secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034822
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track
--------------------------------------------------------------------------------

- Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.
- ADHD portfolio net revenue $13.2M; ex-rebate up 10% YoY on price increases and improved gross-to-nets.
- Net income $2.0M ($0.21 basic EPS) vs $1.5M ($0.24) prior year; includes $3.8M derivative warrant gain.
- Adjusted EBITDA $(0.6)M includes EXXUA launch investments; cash $32.6M at Sep 30.
- EXXUA (gepirone) on track for commercial launch in Q4 2025; patent extended to Sep 2030; targeting $22B MDD market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/0001437749-25-034822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/aytu20250924_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer